MDRX · Veradigm Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2024 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Revenue | $594.41M | $588.02M | $1.50B | $1.50B | $1.77B | $1.39B |
| Cost of Revenue | $292.17M | $279.60M | $883.47M | $937.00M | $1.06B | $1.03B |
| Gross Profit | $302.25M | $308.42M | $619.57M | $565.70M | $713.58M | $724.54M |
| R&D | $108.25M | $97.89M | $193.67M | $206.06M | $254.51M | $268.41M |
| SG&A | $269.41M | $169.20M | $313.81M | $389.94M | $419.77M | $450.97M |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $45.78M | $115.92M | $176.14M | $192.27M | $207.11M | $192.35M |
| Operating Income | ($194.66M) | ($27.10M) | $77.20M | ($130.88M) | ($24.46M) | ($93.05M) |
| Interest Expense | $15.04M | $6.35M | $13.17M | $34.10M | $43.17M | $50.91M |
| Income Tax | $69.49M | ($43.81M) | $27.85M | ($16.69M) | ($23.91M) | $469.0K |
| Net Income | ($291.54M) | ($86.46M) | $134.44M | $700.41M | ($182.18M) | $363.74M |
| EPS - Basic | ($2.70) | ($0.77) | $1.03 | $4.40 | ($1.10) | $2.07 |
| EPS - Diluted | ($2.70) | ($0.77) | $0.97 | $4.40 | ($1.10) | $2.04 |
Balance Sheet
| Line item | FY 2024 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $453.94M | $446.59M | $188.35M | $531.10M | $129.67M | $174.24M |
| Accounts Receivable | $110.92M | $119.15M | $327.07M | $347.36M | $459.75M | $465.26M |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $58.68M | $30.84M | $16.84M | $35.91M | $104.01M | $73.17M |
| Current Assets | $716.00M | $679.65M | $761.34M | $1.15B | $841.26M | $858.97M |
| Total Assets | $1.49B | $1.50B | $2.43B | $2.92B | $3.21B | $3.18B |
| Current Liabilities | $452.17M | $230.31M | $547.08M | $934.78M | $1.21B | $797.73M |
| Long-term Debt | $0 | $200.40M | $350.06M | $167.59M | $551.00M | $647.54M |
| Total Liabilities | $511.44M | $487.22M | $1.02B | $1.25B | $1.92B | $1.60B |
| Stockholders' Equity | $1.07B | $1.02B | $1.41B | $1.67B | $1.29B | $1.55B |
| Retained Earnings | $689.00M | $645.81M | $767.56M | $633.12M | ($49.34M) | $132.84M |
Cash Flow
| Line item | FY 2024 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($20.02M) | $115.56M | ($75.43M) | ($106.72M) | $46.25M | $67.89M |
| Investing Cash Flow | ($125.67M) | $585.15M | ($12.18M) | $1.62B | ($161.06M) | $248.01M |
| Financing Cash Flow | ($6.65M) | ($444.91M) | ($258.87M) | ($1.11B) | $67.34M | ($292.98M) |
| CapEx | $1.55M | $2.06M | $5.29M | $17.02M | $16.60M | $31.31M |
| Free Cash Flow | ($21.58M) | $113.50M | ($80.72M) | ($123.74M) | $29.65M | $36.58M |
Ratios
| Metric | FY 2024 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 50.8% | 52.5% | 41.2% | 37.6% | 40.3% | 52.3% |
| Operating margin | -32.7% | -4.6% | 5.1% | -8.7% | -1.4% | -6.7% |
| EBITDA margin | -25.0% | 15.1% | 16.9% | 4.1% | 10.3% | 7.2% |
| Net margin | -49.0% | -14.7% | 8.9% | 46.6% | -10.3% | 26.2% |
| Free cash flow margin | -3.6% | 19.3% | -5.4% | -8.2% | 1.7% | 2.6% |
| FCF / Net income | 0.07 | -1.31 | -0.60 | -0.18 | -0.16 | 0.10 |
| R&D / Revenue | 18.2% | 16.6% | 12.9% | 13.7% | 14.4% | 19.4% |
| SG&A / Revenue | 45.3% | 28.8% | 20.9% | 25.9% | 23.7% | 32.5% |
| Effective tax rate | - | - | 17.2% | -2.4% | - | 0.1% |
| Return on assets | -19.6% | -5.7% | 5.5% | 24.0% | -5.7% | 11.4% |
| Return on equity | -27.4% | -8.5% | 9.5% | 42.0% | -14.2% | 23.5% |
| Return on invested capital | -14.4% | -1.8% | 3.6% | -7.1% | -1.1% | -4.2% |
| Liquidity | ||||||
| Current ratio | 1.58 | 2.95 | 1.39 | 1.23 | 0.69 | 1.08 |
| Quick ratio | 1.58 | 2.95 | 1.39 | 1.23 | 0.69 | 1.08 |
| Cash ratio | 1.00 | 1.94 | 0.34 | 0.57 | 0.11 | 0.22 |
| Leverage | ||||||
| Debt / Equity | 0.00 | 0.20 | 0.25 | 0.10 | 0.43 | 0.42 |
| Debt / Assets | 0.00 | 0.13 | 0.14 | 0.06 | 0.17 | 0.20 |
| Debt / EBITDA | - | 2.26 | 1.38 | 2.73 | 3.02 | 6.52 |
| Interest coverage | -12.9x | -4.3x | 5.9x | -3.8x | -0.6x | -1.8x |
| Equity multiplier | 1.40 | 1.48 | 1.72 | 1.75 | 2.49 | 2.05 |
| Liabilities / Assets | 0.34 | 0.32 | 0.42 | 0.43 | 0.60 | 0.50 |
| Efficiency | ||||||
| Asset turnover | 0.40 | 0.39 | 0.62 | 0.52 | 0.55 | 0.44 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 68d | 74d | 79d | 84d | 95d | 123d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | 73d | 40d | 7d | 14d | 36d | 26d |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | 19.0x | 3.3x | - | - |
| P / B | 1.0x | 1.9x | 1.8x | 1.4x | - | - |
| P / S | 1.8x | 3.4x | 1.7x | 1.5x | - | - |
| EV / EBITDA | - | 19.5x | 10.7x | 31.5x | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | -60.9% | 0.0% | -15.2% | 27.8% | -23.3% |
| Revenue CAGR (3y) | -26.6% | -30.8% | 2.7% | -6.0% | 4.6% | -0.0% |
| Revenue CAGR (5y) | -19.6% | -20.1% | -0.6% | 1.6% | 5.2% | 0.2% |
| Gross profit growth (YoY) | - | -50.2% | 9.5% | -20.7% | -1.5% | -7.4% |
| Operating income growth (YoY) | - | - | - | -435.2% | 73.7% | - |
| Net income growth (YoY) | - | - | -80.8% | - | - | - |
| EPS growth (YoY) | - | - | -78.0% | - | - | - |
| EPS CAGR (3y) | - | - | -21.9% | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | 34.8% | - | -18.9% | -83.6% |
| FCF CAGR (5y) | - | -12.6% | - | - | -31.5% | 39.8% |
| Book value growth (YoY) | - | -27.7% | -15.5% | 29.6% | -17.1% | 38.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Business segments
$594.41M totalProvider$473.06M · 79.6%
Payer$67.31M · 11.3%
Life Science$54.04M · 9.1%
Geographic
$594.41M totalUS$593.71M · 99.9%
Non Us$699.0K · 0.1%
Stability scores
Altman Z′
FY 2024 · bankruptcy risk
1.39
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2024 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- -ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- -Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Services-Computer Integrated Systems Design
Comparing Veradigm Inc. against the 5 most active filers in the same SIC group.
Dividends
$0.00/share trailing 12 months
| Ex-date | Per share |
|---|---|
| Oct 13, 2008 | $5.2300 |